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Getting sick from Sic
 
etting go may be hard to do, but Nancy Hoe, James 
Musser (National Institutes of Health, Hamilton, MO), 
and colleagues have found that certain successful 
 
Streptococci
 
 
actually avoid attachment to host cells. This contrasts with 
the modus operandi of most pathogenic bacteria.
The M1 serotype of the highly 
heterogeneous Group A 
 
Streptococcus
 
 (GAS) pathogen is 
the most common GAS strain found 
in severe disease outbreaks. M1 
GAS are unique in that they 
produce streptococcal inhibitor 
of complement (Sic), the loss of 
which impairs the ability of the pathogen to colonize the 
upper respiratory tract of mice. “The old dogma was that 
successful colonization necessarily involves adherence,” 
says Hoe. “That’s what led us to look at Sic, to see if it helps 
the bacteria adhere to host cells.”
Unexpectedly, Sic inhibited adhesion to human epithelial 
cells. Sic was internalized into host cells, where it interacted 
with ezrin and moesin, proteins that link actin to the plasma 
membrane during the formation of microvilli. Host cells 
containing Sic lost their microvilli, structures that may be 
important for GAS–host cell interaction. Bacteria lacking Sic 
were also more susceptible to phagocytosis (another actin-
dependent process) by leukocytes. Hoe believes Sic is 
important early in infection, when few bacteria are present and 
maintaining numbers is crucial. This enhanced ability to persist 
contributes to the ability of M1 GAS to cause epidemics.
 
 
 
 
 
Reference: Hoe, P., et al. 2002. 
 
Proc. Natl. Acad. Sci. USA.
 
 
99:7646–7651.
L
Bacteria with Sic 
(black bar) escape 
killing by phagocytes.
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How tumors escape oblivion
 
umors can proliferate by escaping 
failsafe programs such as apoptosis 
and senescence, according to Clemens 
Schmitt, Scott Lowe (Cold Spring Harbor 
Laboratory, Cold Spring Harbor, NY), 
and colleagues. Although the disabling 
of apoptosis was well established as 
an escape mechanism during tumor 
development, the incapacitation of the 
senescence pathway is now shown to 
be an important predictor of response 
to drug therapy.
Lowe and colleagues first examined 
which functions of p53 are needed to 
suppress tumor development in mice. 
They found that a complete block of 
apoptosis (using a dominant apoptosis 
inhibitor) removed all selective pressure 
of pretumorigenic cells to lose p53, and 
could reproduce the aggressive growth 
phenotype normally seen after p53 loss. 
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A time for cytokinesis
 
hink of cell division, and you probably imagine two phases occurring 
in successive order: first mitosis, then cytokinesis. But unlike in 
yeast, mitosis in animal cells does not have to come to completion for 
cytokinesis to commence. Rather, what is important is the inactivation 
of the mitotic spindle checkpoint, according to new results from Brad 
Shuster and David Burgess (Boston College, Boston, MA).
Shuster and Burgess have revisited an old 
experiment, which demonstrated that cytokinesis 
could be initiated prematurely in embryonic 
animal cells by shortening the distance between 
the spindle poles and the cell cortex. “In the old 
experiments,” says Burgess, “they did not have 
the ability to image chromosomes, and so they 
did not know the stage of mitosis when furrows 
were initiated.” Now, armed with better imaging 
tools, the authors have determined that furrow 
formation can be initiated by manipulating the 
spindle only after the chromosomes begin to 
separate. Cells arrested in anaphase, but not 
those in metaphase, could initiate cytokinesis.
This effect may be mediated by the release of a positive effector 
of cytokinesis or by inhibition of a negative regulator. This factor acts 
locally, as arresting one of a pair of spindles within the same cytoplasm 
did not prevent the second from forming a furrow. Yet, a secondary 
furrow could not form between the two spindle sets, indicating that 
the component at the metaphase aster dominates. It is possible that a 
proteolytic effector of the anaphase promoting complex degrades an 
inhibitor of cytokinesis. 
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Furrows form in 
cells stuck in 
anaphase (top) but 
not metaphase.
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This suggests that other p53-related 
phenotypes, such as aneuploidy and 
defective cell cycle checkpoints, are 
unimportant byproducts of p53 loss. “To 
those who believe that the initial event 
[of p53 loss] is to provide genomic insta-
bility,” says Schmitt, “this is a surprise.”
Once drug therapy begins, however, 
one of those previously irrelevant 
byproducts becomes important. Drugs 
can apparently put some cells out of 
commission by sending them into a 
stress-induced senescence, but this 
pathway is dependent on the normal 
function of both p53 and the p16INK4a 
tumor suppressor. Cells that lack the 
wild-type versions of one or both of 
these proteins can avoid senescence, 
and such cells are associated with a 
poor response to drug treatment.
Restoration of the senescence pathway 
Cells suppress tumors using both apoptosis 
and senescence.
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may be one way to improve existing 
chemotherapies. But the effectiveness of 
this treatment will depend on just how 
irreversible the senescent state really 
is—a problem that Schmitt and Lowe 
intend to investigate next.
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